Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

A Phase 2 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy

This is a phase 2 study to evaluate the safety and effectiveness of light-activated talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).

Study Overview

• Status: Completed
• Conditions: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia
• Intervention / Treatment: Drug: talaporfin sodium; Device: Transurethral illumination with light emitting diodes; Procedure: Placement

Detailed Description

This is a phase 2 study to evaluate the safety and effectiveness of using light-activated talaporfin sodium in patients with LUTS due to BPH who are candidates for interventional therapy.

The eligible patient will undergo placement of a proprietary drug activator into the prostatic urethra. Following the placement of the drug activator, patients will receive talaporfin sodium at 1 mg/kg intravenously by slow push over 3-5 minutes. Fifteen minutes after injection a light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes.

SAE reporting will occur from the day of treatment (Day 0) through end of study (month 12), inclusive. Any SAE that is still ongoing at the end of the study will be followed until assessed as chronic, stable or resolved.

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 2

Contacts and Locations

Study Locations

• Australia
  • Herston, Australia
    • Royal Brisbane and Women's Hospital Center of Clinical Research
  • Mentone, Australia
    • Bayside Urology
  • Wolloongabba, Australia, QLD 4102
    • Princess Alexandra Hospital
• New Zealand
  • Christchurch, New Zealand
    • Canterbury Urology Research Trust Hiatt Chambers St. George's Medical Centre
  • Nelson, New Zealand
    • Roundhay Medical Centre
  • Tauranga, New Zealand
    • Tauranga Urology Research, Ltd.
  • Wellington, New Zealand
    • Wellington Urology Research Group Wakefield Urology
  • Whangarei, New Zealand
    • Kensington Hospital Cardinal Points Specialist Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Males, aged 50 years or older with prior diagnosis of BPH;
2. Patients may be eligible whether or not they are on medication for LUTS due to BPH.
3. Patients who are candidates for interventional therapy;
4. Patients who understand and have the ability to sign written informed consent prior to any study procedures and/or discontinuation of exclusionary medications;
5. Patients with an International Prostate Symptom Score of ≥ 15 points;
6. Patients with moderate to severe BPH (Bother Score ≥ 3);
7. Maximum urinary flow rate (Qmax) ≤ 15 mL/sec;
8. Post void residual volume (PVR) ≤ 300 mL;
9. Length of prostatic urethra ≥ 4.0 cm.

Exclusion Criteria:

1. Patients with any previous minimally invasive or surgical intervention for BPH.
2. Patients who are currently enrolled in or who have enrolled in another clinical trial for any disease within the past 30 days.
3. Patients with an active urinary tract infection.
4. Patients with a urethral stricture.
5. Patients with interstitial cystitis.
6. Patients with a predominant middle lobe obstruction.
7. Patients who have evidence or history of prostate or bladder cancer or carcinoma in situ of the bladder.
8. Patients with an abnormal digital rectal exam suggestive of carcinoma of the prostate.
9. Patients with an abnormal digital rectal exam suggestive of an indurated nodule.
10. Patients with a PSA of > 10 ng/ml. If the PSA is 4-10 ng/ml, local standard of care should be pursued to ensure the possibility of prostate cancer is followed up and ruled out prior to, entry into the study.
11. Patients who had a biopsy of the prostate within the past 6 weeks.
12. Patients with bleeding diathesis.
13. Patients with clinically significant renal or hepatic impairment.
14. Patients with neurological conditions felt to affect the bladder or a history of a neurogenic or chronically decompensated bladder.
15. Patients who daily use a pad or device for incontinence.
16. Patients who had an episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months, or peripheral arterial disease with intermittent claudication or Leriches syndrome.
17. Patient has an interest in future fertility.
18. Patients with prolonged QT interval at baseline and/or who are currently taking medication that prolongs QT interval ("prolonged QT interval" defined as > 450 ms).
19. Inadequate organ function as evidenced by the following: Platelet count <100,000/mm3; WBC <4,000/mm3; Neutrophils <1,800/mm3; Hemoglobin <10 g/dL; AST and ALT >3 x ULN; Creatinine >1.5 x ULN
20. Known sensitivity to porphyrin-type drugs or known history of porphyria.
21. Inability to avoid bright indoor lighting and sunlight during the first 72 hours after LS11 administration.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: LS11 (talaporfin sodium)

Drug: talaporfin sodium; LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes); Other Names: LS11; Device: Transurethral illumination with light emitting diodes; A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes; Procedure: Placement; Placement of device in prostate urethra

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety of light-activated talaporfin sodium by recording of Adverse Events; Preliminary effectiveness of light-activated talaporfin sodium by evaluating the International Prostate Symptom Score (IPSS) along with Bother Score (BS).	12 months

Collaborators and Investigators

• Sponsor: Light Sciences Oncology

Study record dates

Study Major Dates

• Study Start: May 1, 2009
• Primary Completion (Actual): February 1, 2011
• Study Completion (Actual): February 1, 2011

Study Registration Dates

• First Submitted: June 9, 2009
• First Submitted That Met QC Criteria: June 10, 2009
• First Posted (Estimate): June 11, 2009

Study Record Updates

• Last Update Posted (Estimate): November 16, 2012
• Last Update Submitted That Met QC Criteria: November 14, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Keywords: LUTS; BPH; talaporfin sodium
• Additional Relevant MeSH Terms: Pathologic Processes; Urological Manifestations; Prostatic Diseases; Prostatic Hyperplasia; Hyperplasia; Lower Urinary Tract Symptoms; Antineoplastic Agents; Photosensitizing Agents; Dermatologic Agents; Talaporfin
• Other Study ID Numbers: LSO-OL012